ZYBTNasdaqPharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$1.45+0.05 (+3.57%)
Close on Oct 19, 2026
Share price
−$1.21 (−45.49%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Zhengye Biotechnology Holding Ltd saw revenue fall 37.6% to CN¥116.36M over fiscal 2025. Operating income fell 528.9% to -CN¥70.51M, moving the operating margin from 8.8% to -60.6%. Free cash flow was CN¥12.33M, down 55.1% from a year earlier.
Revenue
CN¥116.36M
-37.6% vs. a year earlier
Operating income
-CN¥70.51M
-528.9% vs. a year earlier
Free cash flow
CN¥12.33M
-55.1% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- CN¥116.36M
- Net income
- -CN¥69.78M
- Free cash flow
- CN¥12.33M
Valuation needs the share price. It fills in once daily prices are connected and converted from CNY.
Five years at a glance
Fiscal years 2021 to 2025, CNY
Revenue
CN¥116.36M-37.6% YoY
Gross profit
CN¥23.87M-73.9% YoY
Operating income
-CN¥70.51M-528.9% YoY
Net income
-CN¥69.78M-717.0% YoY
EPS, diluted
–
Free cash flow
CN¥12.33M-55.1% YoY
Reported period